Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

Kumar, Shaji; Jacobus, Susanna; D. Cohen, Adam; Weiss, Matthias; S. Callander, Natalie; A. Singh, Avina; L. Parker, Terri; R. Menter, Alex; Yang, Xuezhong; M. Parsons, Benjamin; Kumar, Pankaj; Kapoor, Prashant; S. Rosenberg, Aaron; A. Zonder, Jeffrey; A. Faber, Edward; Lonial, Sagar; G. Richardson, Paul; Z. Orlowski, Robert; I. Wagner, Lynne; Vincent Rajkumar, S.

doi:10.1200/jco.2020.38.18_suppl.lba3

Public

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

Published in Journal of Clinical Oncology • Jun 1, 2020

Authors:

Shaji Kumar

Susanna Jacobus

Adam D. Cohen

Abstract

LBA3 Background: Bortezomib (btz) combined with lenalidomide (len) and dexamethasone (dex) (VRd) is a standard initial therapy for NDMM. Carfilzomib (cfz), a next-generation proteasome inhibitor, in combination with len-dex (KRd) has shown higher efficacy in phase II trials. This randomized phase II...

Subject

Lenalidomide

Medicine

Carfilzomib

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!